Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders-Reference-Cited by-同舟云学术

Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders

Published:2018-09-18 Issue:11 Volume:320 Page:1151
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Ossenkoppele Rik¹²,Rabinovici Gil D.³,Smith Ruben¹,Cho Hanna⁴,Schöll Michael¹⁵,Strandberg Olof¹,Palmqvist Sebastian¹,Mattsson Niklas¹⁶,Janelidze Shorena¹,Santillo Alexander¹,Ohlsson Tomas⁷,Jögi Jonas⁸,Tsai Richard³,La Joie Renaud³,Kramer Joel³,Boxer Adam L.³,Gorno-Tempini Maria L.³,Miller Bruce L.³,Choi Jae Y.⁹¹⁰,Ryu Young H.⁹,Lyoo Chul H.⁴,Hansson Oskar¹⁶

Affiliation:

1. Lund University, Clinical Memory Research Unit, Lund, Sweden

2. VU University Medical Center, Department of Neurology and Alzheimer Center, Amsterdam Neuroscience, Amsterdam, the Netherlands

3. Memory and Aging Center, Department of Neurology, University of California San Francisco

4. Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea

5. Wallenberg Centre for Molecular and Translational Medicine and the Department of Psychiatry and Neurochemistry, University of Gothenburg, Gothenburg, Sweden

6. Memory Clinic, Skåne University Hospital, Malmö, Sweden

7. Skåne University Hospital, Department of Radiation Physics, Lund, Sweden

8. Skåne University Hospital, Department of Clinical Physiology and Nuclear Medicine, Lund, Sweden

9. Department of Nuclear Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea

10. Division of RI-Convergence Research, Korea Institute Radiological and Medical Sciences, Seoul, South Korea

Publisher

American Medical Association (AMA)

Subject

General Medicine

Reference40 articles.

1. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010.;Beach;J Neuropathol Exp Neurol,2012

2. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease.;McKhann;Alzheimers Dement,2011

3. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis.;Ossenkoppele;JAMA,2015

4. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.;Jansen;JAMA,2015

5. Limited agreement between biomarkers of neuronal injury at different stages of Alzheimer’s disease.;Alexopoulos;Alzheimers Dement,2014

Cited by 317 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diagnosis and therapy of Alzheimer's disease: Light-driven heterogeneous redox processes;Advances in Colloid and Interface Science;2024-10

2. A novel plasma p-tau181 assay as a specific biomarker of tau pathology in Alzheimer's disease;Translational Neurodegeneration;2024-09-03

3. Tau PET positivity predicts clinically relevant cognitive decline driven by Alzheimer’s disease compared to comorbid cases; proof of concept in the ADNI study;Molecular Psychiatry;2024-08-23

4. Binding adaptability of chemical ligands to polymorphic α-synuclein amyloid fibrils;Proceedings of the National Academy of Sciences;2024-08-22

5. Rationale and design of the BeyeOMARKER study: prospective evaluation of blood- and eye-based biomarkers for early detection of Alzheimer’s disease pathology in the eye clinic;Alzheimer's Research & Therapy;2024-08-21